Advertisements

Don’t Give Your Kids An Inheritance, Give This Instead

What Can Be Better Than An Inheritance? A Personal Matching Program

Getting an inheritance can be a good thing – or a bad thing.

While Millennials may wish their inheritance will someday pay for their retirement, that may or may not happen. According to a 2018 Charles Schwab Study, more than half (53%) of young people ages 16-25, “believe their parents will leave them an inheritance, versus the average 21% of people who actually received an inheritance of any kind.”

And, if they do receive an inheritance when they are close to retirement, that may not help them. It turns out that one out of three Baby Boomers who received an inheritance spent it within two years, according to research conducted by Dr. Jay Zagorsky, Senior Lecturer at Boston University Questrom School of Business, based on data from the Federal Reserve and a National Longitudinal Survey funded by the Bureau of Labor Statistics that studied the period 1985-2008.

A Better Option: A Savings Program With A Kick

Wouldn’t it be a better option to help youthful members of the family set up a savings program with a kick to it – a match that you arrange to ignite interest, leverage time and boost returns through compounding?

Let’s say your son “Steve” is a 20-year-old college student who lives at home with you. Steve has a part-time job during the school year and works full time over summer breaks.

Steve hasn’t developed a rule set for saving money. He is not eligible for a 401(k) at work. He is not thinking about a far-off retirement, but he believes he might benefit from a nice inheritance, probably just when he might need the money when he retires.

As Steve’s Mom or Dad, you know better. You’d like Steve to learn how to become financially secure in his own right.

Let’s Make A Deal

Here’s how you can help. You make a deal with Steve:

“For every dollar you save, I will match you dollar-for dollar for five years. But there is a catch. My match goes into a retirement plan for you, a Roth IRA, that you must agree not to touch until you retire someday in the far away future.” 

That gives Steve something to think about. If he saved, say $500 a month of his own money, he would have $30,000 of savings in five years. He would also have an additional $30,000 funded by his parents in a Roth IRA that he would agree not to touch. Nothing wrong with that deal. . . But what about the constraint on not using that Roth money until retirement?

Maximizing Roth Limits While Avoiding Gift Taxes

That $500 monthly ($6,000 yearly) figure is magical.

It is the maximum ($6,000) that can be contributed to a Roth IRA per year, the annual limit for funding a Roth, according to the IRS.

It also happens to avoid a gift tax obligation (the parents’ match is a gift). Since $6,000 is well under the $15,000 annual exclusion, Steve’s parents would not be subject to gift taxes for funding the Roth. (Read “IRS Announces High Estate And Gift Tax Limits For 2020.”)

Will Steve Accept The Offer?

For Steve to see the full potential of the matching program, you’ll want to show him what the Roth can accomplish over the decades between now (age 20) and age 65, a period of 45 years. The Roth will need to be invested for long-term capital appreciation potential. The best way to do that is through a simple S&P 500 Index Fund.

What If The 45 Years Turn Out To Be Terrible Markets?

This is where history comes in handy.

For skeptics, we can look at the worst performing 45 year market periods since the 1920s. For the optimists, we can review the best. While history will not repeat itself exactly, history does provide a frame of reference.

Let’s go back in time to see the worst outcome for a five year program of monthly investments in an S&P 500 Index Fund with a 45 year horizon.

That 45-year period ended with the Financial Crisis (1963-2008).

Had Steve started his five-year, $500 a month program ($30,000 invested) at the worst of times, his age 65 value would have grown to $1,192,643, an average annual return of 9%.

What If The Next 45 Years Turn Out To Be Terrific Markets?

If Steve had lucked into the best 45 year period (1946-1991), he would have had $4,368,046 at age 65 (highest 45-year holding period), an average annual return of 12.4%.

What If Returns Are Just Average?

What about the median return (1931-1976)? Steve would have had $2,421,743 at age 65, an average annual return of 10.9%.

What If Steve Wanted Safety Over Capital Appreciation?

If Steve had been very conservative, he may have considered the safest option, a money market fund that tracked 90 day T-Bills. The best 45-year period for money market funds (1956-2001) would given Steve an age-65 retirement nest egg of only $356,519, a 6% average annual return.

You can see these comparisons graphically in the chart below.

The point is this: Steve can’t control what type of market he will experience. But history can give him a frame of reference.

Is Steve Convinced?

To accept his parent’s matching proposal, Steve needs to see the benefit of investing in himself (and having others invest in him through the match). His interest needs to be ignited through the math behind the market, the math that leverages time and boosts returns through compounding.

Your Role As A Parent

As we approach the holidays, there will be opportunities to get together with young adults in your family. Why not impart some sage advice – in fact, not just once, but as often as possible.

Your Advice

Start saving now in a Roth IRA. Fund your 401(k) at work as soon as you become eligible; contribute each payroll period without stopping until you retire; maximize your match. Choose investments based on long-term capital appreciation potential. Take advantage of the math of compounding. And, if a parent or family member is willing to match your savings, go for it.

Survey Question

After reading this post, what is the likelihood that you will make a Roth matching proposal with your child, grandchild, niece or nephew? I’d like to know what you think. Click here to take a quick survey.

Look for my next post on what happens when someone in Steve’s position starts contributing to his 401(k) at work.

Follow me on Twitter or LinkedIn. Check out my website.

I got my start on Wall Street as a lawyer before moving to money management more than 25 years ago. My firm, Jackson, Grant Investment Advisers, Inc. (www.jacksongrant.us) of Stamford, CT, is a fiduciary high-net-worth boutique specializing in managing retirement portfolios. I approach investing with a blend of optimism (everyone can do something to improve their financial situations) and a dose of healthy skepticism (don’t invest unless you understand what can go wrong). These themes describe my “voice” whether on-air (NBC Nightly News, CNBC, NPR) or presenting (AARP, AAII, BetterInvesting) or in print. I began writing in earnest in 1996 (You and Your 401(k), an investor’s view of 401(k)s). Recent books are: Retire Securely (2018), offering concise action-oriented insights for retirees, pre-retirees and Millennials (Excellence in Financial Literacy Award “EIFLE”); The Retirement Survival Guide (2009/2017), a comprehensive tool chest for all financial levels and ages (EIFLE Award); and Managing Retirement Wealth (2011/2017), a guide for high net worth individuals (EIFLE Award). I’ve written over 1,000 weekly columns (Clarion Award, syndicated by King Features). When the time is right, I comment on SEC rule proposals.

Source: Don’t Give Your Kids An Inheritance, Give This Instead

372K subscribers

This is Stock Market For Beginners 2019 edition video! This video should help out all beginners in the stock market who want to know how to invest in the stock market in 2019. I try to do a stock market for beginners video each year and this is the 2019 edition. We will discuss how to buy stocks, where to buy stocks, how much money do you need to buy stocks, how to invest in the stock market, what is the best brokerage for buying stocks and so much more. I hope you get a tremendous amount of value out of this stock market for beginners video today. Enjoy! Learn How I pick Stocks in this course linked below. Enjoy! https://bit.ly/2DT5ER9 Learn How To Make Money From Trading Stock Options Here https://bit.ly/2QaHSX6 To join my private stock group click below. https://bit.ly/2OSUMDS * My Instagram is : FinancialEducationJeremy Financial Education Channel Sign Up to Get The Top 5 Investing Apps I Use And How I Use Them http://bit.ly/jeremystop5

Advertisements

Silicon Valley Investors Are Bonkers For European Startups

Index Ventures partner Danny Rimer always planned to move back to London from Silicon Valley. But when Rimer returned to England a year ago after seven years establishing Index’s U.S. foothold with stakes in companies like Dropbox, Etsy and Slack, he had company: investors from U.S. venture capital firms Benchmark, NEA and Sequoia were also appearing at startup dinners, leading deals and even looking to open offices.

“We’ve always been surprised at how our U.S. peers flew over Europe,” says the Canada-born and Switzerland-raised Rimer, 49, who opened Index’s London office in 2002. As a full-time European resident again, he debuts at No. 3 on the 2019 Midas List Europe, thanks to multi-national investments including Discord, Glossier, Farfetch and Squarespace. Rimer says he watched as investors flocked to pour money into India, China, and Latin American countries, instead. “A very successful Welshman talked about Europe being a museum,” says Rimer, alluding to billionaire investor Michael Moritz, the Sequoia partner and Google and Yahoo investor who moved from Wales to Silicon Valley decades ago. “Now his firm is all over the geo looking.”

More money is flowing into European tech than ever, and it’s increasingly coming from venture capital’s elite U.S. firms. European startups are likely to receive a record $34.3 billion in investments this year, according to investment firm Atomico, with 19% of funding rounds including an American firm, double the portion when Atomico started tracking in 2015. Those American investors will account for about $10 billion, or nearly one-third, of the total amount invested.

American interest in European companies isn’t new: Palo Alto, California-founded Accel opened a London office nearly twenty years ago, and other firms followed suit. But many retreated in subsequent economic down cycles, says Philippe Botteri, No. 6 on Midas List Europe. Botteri, a French citizen, started his venture career at Bessemer Venture Partners in San Francisco and joined Accel in London in 2011. The years leading up to the U.S. firms’ return witnessed a global economic crisis, while access to customers, engineering talent and programs like startup accelerator Y Combinator drove a host of European founders, such as Stripe’s Collison brothers, to relocate to the U.S. Considered a splintered market with regional regulations and languages, Europe faced a fresh hurdle with “Brexit,” when the United Kingdom voted in a 2016 referendum to leave the European Union, a process still ongoing. Its ruling body, the European Union, has made an anchor policy of challenging big tech companies on how they use data.

Blossom Capital founder Ophelia Brown says she was met with incredulity when, as a young investor at Index Ventures between 2012 and 2016, she visited West Coast counterparts and described the opportunity in European tech. “Everyone would push back: Europe was a little travel, a little ecommerce, a little gaming,” she says. “They felt there was nothing of substance.” In 2017, when she set out to raise Blossom’s first fund, many U.S. investors told her the opportunity for new firms seemed greater in the U.S. and China. Just two years later, Brown says she now hears from institutions asking how to get more exposure to Europe’s startup scene.

What’s changed: A mix of high-profile public offerings such as Adyen and Spotify and a maturing ecosystem that’s made it a much easier draw for U.S. firms, facing intense competition at home, to risk millions in Europe. Spotify, the Stockholm-based music streaming service that went public via direct listing in April 2018, and Adyen, the Amsterdam-based payments company that went public two months later, have created nearly $50 billion in combined market value. The IPOs of Criteo in Paris and Farfetch in London have also produced a network of millionaires primed to write “angel investor” personal checks into smaller tech companies. Today there are 99 unicorns, or companies valued at one billion dollars or more, compared to 22 in 2015, according to Atomico’s data.

“The question used to be, can Europe generate a $1 billion outcome, and then you had Spotify and Adyen creating tens of billions of market cap,” says Botteri, who notes that winners are also coming from a broader base of cities in Europe – 12 hubs, not all from London and Tel Aviv. (As on the Midas List Europe, European investors often include Israel’s tech-heavy startup scene.) “Now the question is, can Europe generate a $100 billion company? And my answer is, just give it a few years.”

For startups in far-flung places like Tallinn, Estonia, where Pipedrive was founded in 2010, or Bucharest, where UiPath got its start, the influx of U.S. venture capital counts for more than just money – it means access to former operators who helped scale businesses like Facebook, Google and Slack, introductions to customers in New York or executive hires in San Francisco. And with their stamps of approval comes buzz that can still kickstart a startup’s brand recognition, investors say.

But they also come with a risk: heightened pressure to deliver, board members who may be 5,000 miles away, and potentially overheated valuations that can prove onerous should a founder misstep. Sarah Noeckel, a London-based investor at Dawn Capital and the publisher of women-in-tech newsletter Femstreet, has tracked a number of recent seed-stage deals in which a U.S. investor swooped in with an offer too rich for local alternatives to match, for companies that sometimes haven’t sold anything yet. “I think there’s little validation at this point how it actually plays out for them,” she says.

For the U.S. investors, there’s a clear financial incentive to “swoop in.” On average over the past year, one dollar’s worth of equity in a European startup in a Series A funding round would have cost $1.60 in the U.S. for a comparable share, according to the Atomico report. Investors insist that for the most in-demand companies in Europe, such as London-based travel startup Duffel, which raised $30 million from Index Ventures in October, prices already match Silicon Valley highs.

All the more reason that as U.S. investors hunt in Europe like never before, they’re doing so quietly. Though Lightspeed Venture Partners announced its hiring of a London-based partner, Rytis Vitkauskas, in October, other U.S. firms have been on the ground without advertising it publicly. Leaders from NEA, with $20 billion in assets under management, passed through London in recent weeks on a venture capital tour as the firm plans to invest more heavily in Europe moving forward, sources say. Sequoia partners Matt Miller and Pat Grady, meanwhile, have been spotted around town meeting with potential job candidates. (Sequoia’s never employed a staffer in Europe before.) NEA and Sequoia declined to comment.

“Everyone would push back: Europe was a little travel, a little ecommerce, a little gaming. They felt there was nothing of substance.”

Blossom Capital founder Ophelia Brown

Many more U.S. investors now pass through London; some even stretch the meaning of what it means to visit a city through months-long stays. “I always used to have to travel to the West Coast to see friends that I made from the show,” says Harry Stebbings, who has interviewed hundreds of U.S. venture capitalists on his popular podcast, ‘The Twenty Minute VC.’ “Now, every week I can see three to five VCs in London visiting.” For the past several months, longtime Silicon Valley-based Accel partner Ping Li has lived in London with his family. Asked if he’d moved to the city without any public announcement, Li demurred – “I would argue that I’m spending a lot of time on British Airways,” he says – before insisting he plans to return to California in three to six months. “I don’t think you can actually be a top-tier venture capital firm without being global,” he says. Firms without plans for a permanent presence in London are creating buzz among local investors, too. Kleiner Perkins investors Mamoon Hamid and Ilya Fushman have been active in Europe recently, they confirm. Benchmark, the firm behind Snap and Uber, invested in Amsterdam-founded open-source software maker Elastic, which went public in 2018, and more recently London-based Duffel and design software maker Sketch, based in The Hague. “Europe’s just more in the spotlight now,” partner Chetan Puttagunta says.

Against the backdrop of Brexit, the inbound interest can feel like a surprise. London-based investors, however, appear to be shrugging off concerns and hoping for the best. “In and of itself, it means nothing,” says Index Ventures’ Martin Mignot, a French and British citizen investing in London and No. 7 on the Midas List Europe. “The only real question is around talent, whether it’s going to be more difficult for people to come and work in London, but how difficult that is remains to be seen.” Or as his colleague Rimer quips: “Having spent seven years in the U.S., I don’t exactly think the political climate of the U.S. was necessarily more welcoming.”

When Rimer attended the Slush conference, a tech conference of 25,000 in Helsinki in November, he brought along a guest: Dylan Field, the CEO of buzzy San Francisco-based design software maker Figma. If Field were European, Index would be leading him around Silicon Valley; instead, with 80% of Figma’s business outside of the U.S., Rimer wanted Field to experience the energy of Europe’s tech community first-hand. Explains Rimer: “It’s just a reflection of the reality today.”

Get Forbes’ daily top headlines straight to your inbox for news on the world’s most important entrepreneurs and superstars, expert career advice, and success secrets.

Follow me on Twitter or LinkedIn. Check out my website. Send me a secure tip.

I’m an associate editor at Forbes covering venture capital, cloud and enterprise software out of New York. I edit the Midas List, Midas List Europe, Cloud 100 list and 30 Under 30 for VC. I’m a Fortune Magazine and WNYC alum. My tech focus would’ve perplexed my college self, as I studied medieval history and archaeology at Harvard University. Follow me on Twitter at @alexrkonrad and email me at akonrad@forbes.com. Securely share tips at https://www.forbes.com/tips/

Source: Silicon Valley Investors Are Bonkers For European Startups

120K subscribers
A interview with Venture Capitalist and Co-Founder of Andreessen Horowitz, Marc Andreessen In this interview, Marc discusses how Silicon Valley works and why it is so hard to replicate. Marc also talks about what he looks for in investments and gives advice to students. 📚 Marc Andreessen’s favourite books are located at the bottom of the description❗ Like if you enjoyed Subscribe for more:http://bit.ly/InvestorsArchive Follow us on twitter:http://bit.ly/TwitterIA Other great Venture Capitalists videos:⬇ Marc Andreessen: Venture Capital Investment Philosophy:http://bit.ly/MAndreessenVid1 Billionaire Chris Sacca on Investing, Venture Capital and Life:http://bit.ly/CSaccaVid1 Billionaire Peter Thiel on Entrepreneurship, Innovation and Competition: http://bit.ly/PTheilVid1 Video Segments: 0:00 Introduction 1:58 Something you really screwed up? 3:09 How does Silicon Valley work? 6:33 Why has Silicon Valley never been replicated? 10:24 Where does the value of cryptocurrency come from? 12:46 Is it going to disrupt governments? 14:26 What makes a fundable company? 19:23 What do you see in the future? 22:48 Advice to students? 24:52 How do you get rid of fear? Marc Andreessen’s Favourite Books🔥 Life: The Movie:http://bit.ly/LifeTheMovie Confessions of an Economic Hit Man:http://bit.ly/ConfessionsEconomic And the Money Kept Rolling In (and Out) Wall Street:http://bit.ly/MoneyKeptRolling Last Call:http://bit.ly/LastCallMA Startup Rising:http://bit.ly/Startuprising Interview Date: 29th March, 2018 Event: Udacity Original Image Source:http://bit.ly/MAndreessenPic1 Investors Archive has videos of all the Investing/Business/Economic/Finance masters. Learn from their wisdom for free in one place. For more check out the channel. Remember to subscribe, share, comment and like! No advertising.

Measuring The Total Economic Impact Of Unified Endpoint Management

Today, the average IT organization is spending at least 5% of their organization’s annual revenue on IT investments – and the cost of each investment spans far beyond its price tag. Each one needs to be deployed and maintained by IT staff that is grappling with more tools and software products than ever before. Of course, supporting an IT staff comes with its own set of costs and challenges. CIOs, CTOs, and their teams are human resource scarce and spread extremely thin, so the opportunity cost of focusing on one tool versus another has never been greater.

This complexity comes at a time where clearly defined IT strategies that bring about positive impact to the business are non-negotiable. According to IDG’s 2019 State of the CIO report, “62% of CIOs say that the creation of new revenue generating initiatives is among their job responsibilities.” 88% claim to be “more involved in leading digital transformation initiatives compared to their business counterparts.” Net-net, the onus is on IT leaders to streamline efficiencies, reduce total cost of ownership (TCO), and net a return on investment (ROI) for the business.

IT investment decisions driven by real customer data

Forrester has been instrumental in helping business decision-makers overcome their resource, budget, and investment challenges by introducing a Total Economic Impact™ (TEI) methodology. Not only does the TEI take costs and benefits into account, but also the time saved and economic impact of strategic decisions made. Forrester’s TEI assessments are drawn from real client experiences with vendor products and services. The team diligently documents customer outcomes to better understand their positive or negative business impact. Consulting this unique research methodology helps business decision makers justify and future-proof their investments.

Making the transition to unified endpoint management

If your organization is like most, it has a mix of devices that employees use to get work done – whether they’re corporate-liable or supported under a bring your own device (BYOD) program. With 464 custom apps deployed across the average enterprise, procuring a means to manage devices and everything on them (not just apps, but also content and data) has become mission-critical for businesses.

Traditionally, mobile device management (MDM), enterprise mobility management (EMM), and client management tools (CMTs) have been relied upon to get the job done. However, business use cases for devices have become more complex and wide ranging. These shifts are necessitating a tool that makes it possible to manage everything from one place. This is unified endpoint management (UEM).

Commissioned by IBM, Forrester Consulting recently conducted a TEI analysis of IBM Security MaaS360 UEM customers to determine whether they are reducing TCO and netting a quick break-even on their investment. The Forrester team took the time to glean feedback from 19 MaaS360 UEM clients representing financial services, nonprofit, utilities, manufacturing, and professional services industries. These individuals are responsible for managing anywhere from 500 to 100,000 devices for their respective businesses each day.

How UEM from IBM resulted in significant ROI1

Across the 19 clients that were interviewed, Forrester identified the following key benefits. These amount to a three-year 160% ROI and payback in less than 3 months:

  • Endpoint configuration: a 96% reduction in time spend provisioning devices
  • End-user setup: a 47% reduction in time spent getting employees up and running
  • Modern management: $22,960 saved from simplifying their management approach
  • Support ticket remediation: 50% fewer tickets and 55% less time taken to resolve them
  • Security breach remediation: 80% reduction in number of incidents experienced

Of course, these benefits were experienced by a composite organization used to represent the 19 customers surveyed by Forrester. Organizations considering UEM that are actively seeking their own customized TEI assessment can now work with IBMers to do just that. Request your own complementary assessment today to understand whether you can expect a return on your UEM investment, and if so, how quickly you can expect your payback period to arrive.

Request a custom Forrester TEI assessment now

1 The Total Economic Impact™ Of IBM MaaS360 With Watson, a commissioned study conducted by Forrester Consulting, April 2019

John Harrington is a Program Director at IBM Security, overseeing product marketing for data security and unified endpoint management (UEM). In this capacity, he works with product managers, product marketers, and account managers to provide guidance for businesses encountering modern cybersecurity challenges. He’s focused on helping clients learn how to establish digital trust and the various ways Guardium and MaaS360 can help them keep their data and endpoints protected. John is also working towards an MBA graduate degree at Villanova School of Business, and spends his spare time exploring the city of Philadelphia with his wife and their two beagles.

Source: IBM Security BrandVoice: Measuring The Total Economic Impact Of Unified Endpoint Management

20 Stocks That Could Double Your Money in 2020

It might be hard to believe, but in just seven weeks we’ll be saying our goodbyes to 2019. Although investors have endured a couple of short-lived rough patches, it’s been an exceptionally strong year for the stock market. The broad-based S&P 500 is up 23%, the iconic Dow Jones Industrial Average has gained 18%, and the tech-heavy Nasdaq Composite has returned almost 27%.

How good are these returns? Well, let’s just say that the S&P 500, inclusive of dividends and when adjusted for inflation, has historically returned 7% annually, with the Dow closer to 5.7% a year, on average, over its 123-year history.

And it’s not just these indexes that stand out. Of companies with a market cap of $300 million or larger, 124 have gained at least 100% year to date, through Nov. 5. Just because the calendar is about to change over to a new year doesn’t mean this optimism can’t carry over.

If you’re looking for a number of intriguing investment ideas for next year, consider these 20 stocks as possible candidates to double your money in 2020.

1. Innovative Industrial Properties

Yes, cannabis real estate investment trusts (REIT) are a real thing, and they can be quite lucrative! Innovative Industrial Properties (NYSE:IIPR), the best-known marijuana REIT on Wall Street, is already profitable and growing at a lightning-quick pace. After beginning 2019 with 11 medical marijuana-growing and processing properties in its portfolio, it now owns 38 properties in 13 states that span 2.8 million square feet of rentable space.

The beauty of Innovative industrial Properties’ business model is that it creates highly predictable cash flow. The company’s weighted-average remaining lease term is 15.6 years, and its average current yield on its $403.3 million in invested capital is a cool 13.8%. At this rate, it’ll net a complete payback on its invested capital in just over five years.

As long as marijuana remains illicit at the federal level in the U.S., access to capital will be dicey for cannabis cultivators. That makes Innovative Industrial’s acquisition-and-lease model a veritable green rush gold mine for 2020.

A user pinning interests to a virtual board while using a tablet.

Image source: Pinterest.

2. Pinterest

If you missed out on the Facebook IPO and have been kicking yourself for the past seven years, don’t fret. Social media photo-sharing site Pinterest (NYSE:PINS), which allows users to create their own virtual boards based on their interests, could be your second chance to profit.

Like most brand-name social media sites, Pinterest has seen exceptionally strong user growth. Monthly active user (MAU) count rose to 322 million by the end of September, up 71 million from the prior-year period. What’s most notable about this growth is that it’s mostly coming from international markets (38% MAU growth vs. 8% in the U.S.). Even though ad-based revenue is minimal in foreign markets, it nevertheless demonstrates that Pinterest has global appeal.

The company is also making serious strides to monetize these users by boosting average revenue per user (ARPU) globally. In recent quarters, Pinterest has simplified its ad system for smaller businesses, focused its efforts on boosting ARPU in overseas markets, and pushed for video, which has a much higher repost rate than static images. These efforts appear to be paying early dividends, with international ARPU more the doubling to $0.13 from $0.06 over the past year.

With Pinterest forecast to push into recurring profitability next year, a doubling of its stock is certainly not out of the question.

A biotech lab researcher using multiple pipettes to fill test tubes.

Image source: Getty Images.

3. Intercept Pharmaceuticals

Never overlook a first-mover advantage — especially when it pertains to a $35 billion indication!

Nonalcoholic steatohepatitis (NASH) is a liver disease that affects between 2% and 5% of all U.S. adults, has no cure or Food and Drug Administration (FDA)-approved treatments, and is expected to be the leading cause of liver transplants by the midpoint of the next decade. And according to Wall Street, it’s a $35 billion untapped disease.

In late September, Intercept Pharmaceuticals (NASDAQ:ICPT) submitted a new drug application for Ocaliva, a treatment for NASH. While the high dose of Ocaliva did lead to an unsettling number of pruritus (itching)-based dropouts in late-stage studies, it also produced a statistically significant reduction in liver fibrosis levels, relative to baseline and the placebo, without a worsening in NASH at the 18-month mark. Even if Intercept’s Ocaliva only secures a small subset of the NASH market, it has the potential, if approved by the FDA, to quickly earn blockbuster status of $1 billion or more in annual sales. Suffice it to say that 2020 could be a banner year for this midcap biotech stock.

A Redfin for sale sign on the front lawn of a home, with a black sold sign attached.

Image source: Redfin.

4. Redfin

With interest rates and mortgage rates on the rise throughout much of 2018, it looked as if the fun had come to an end for a hot housing market. But following a trio of Federal Reserve rate cuts and a big drop in Treasury yields, the housing industry is hotter than it’s been in more than a year. That, along with low mortgage rates, could be the perfect recipe for online real estate brokerage company Redfin (NASDAQ:RDFN) to double in 2020.

Unlike some of the companies you’ll see on this list, profitability isn’t a near-term priority for Redfin. Rather, scaling its tech-driven platform and taking real estate service market share are its primary goals. One way Redfin is doing this is by undercutting traditional real estate agents with its salaried agents. With a listing fee of just 1%, Redfin cuts out costs that generally irritate buyers and sellers.

More so, Redfin is looking to infiltrate the high-margin servicing business to make the buying and selling experience less of a hassle. It’s expanding nationally and consolidating tasks, such as title, appraisal, and home inspection, into a single package that consumers can designate the company to handle, thereby removing a key buying or selling objection. Perhaps it’s no surprise that this real estate disruptor grew sales by 39% in the second quarter and saw its market share rise 11 basis points to 0.94% of U.S. existing home sales from Q1 2019.

Two smiling young women texting on their smartphones.

Image source: Getty Images.

5. Meet Group

The online dating industry is worth, by some accounts, $3 billion in annual revenue, and Meet Group (NASDAQ:MEET), which specializes in livestreaming and social media interaction (including online dating), is a company that growth and value investors should be swiping right on.

Whereas most of the tech world focuses on bigger names with broader brand recognition, Meet Group’s mobile portfolio of apps, which includes MeetMe, Lovoo, Skout, Tagged, and Growl, has done an admirable job of growing the business. More specifically, the company’s laser focus on bolstering its video business is really paying dividends. During the second quarter, daily active video users increased to 892,000, representing 21% of total users where Live is available on their app. This is important given that video revenue per daily active user grew to $0.26 in Q2 2019 from $0.15 in the prior-year quarter.

Furthermore, Meet Group’s big spending on security enhancements is now in the rearview mirror, according to a third-quarter preliminary update. This mobile livestreaming site is growing at a double-digit rate, has a focus on high-margin video, and sports a forward price-to-earnings ratio of eight (yes, eight!). This multiple, and stock, could both easily double and still have room to run.

A prescription drug capsule with a boxing glove coming out of it that's knocking out a cancer cell.

Image source: Getty Images.

6. Exelixis

In all fairness, Exelixis (NASDAQ:EXEL) has had an incredible run on the coattails of lead drug Cabometyx. Following its approval to treat second-line renal cell carcinoma (RCC), and first-line RCC, the company’s share price rose from $4 to $32 between Jan. 2016 and Jan. 2018. Now, back at $16, Wall Street is wondering, what’s next?

In the early months of 2020, Exelixis and partner Bristol-Myers Squibb may have that answer. The duo are expected to reveal results from the CheckMate 9ER late-stage trial that combines Cabometyx with Bristol-Myers’ blockbuster immunotherapy Opdivo, which also happens to be an RCC rival. If this combination therapy dazzles, the duo could snag an even greater share of the RCC market, further boosting Cabometyx’s case as a blockbuster drug.

Investors should also know that Exelixis offers a rare value proposition in the highly competitive and often money-losing biotech space. This is a company offering double-digit sales growth, a forward P/E of 16, and a PEG ratio of a minuscule 0.36. With patent cliffs remaining challenging for Big Pharma, Exelixis, in addition to potentially notching a win with CheckMate 9ER, might find itself as a buyout candidate in 2020.

A person inserting a credit card into a reader in a retail store.

Image source: Getty Images.

7. StoneCo

Although Warren Buffett is best known for buying value stocks, the fastest-growing stock in Buffett’s portfolio (at least from a revenue perspective), StoneCo (NASDAQ:STNE), could be primed to double in 2020.

StoneCo isn’t exactly a household name, but this $10 billion payment solutions and business management software developer is finding plenty of interest for its fintech offerings in Brazil. During the second quarter, which StoneCo reported in mid-August, the company saw total payment volume for its merchants rise 61% year over year, while active clients increased 80% to 360,200 from the prior-year period. Since Brazil remains largely underbanked, there’s a long-tail opportunity for StoneCo to make its mark with small-and-medium-sized businesses in the country.

StoneCo is also investing heavily into its software subscription model. On a sequential quarterly basis, subscribed clients more than doubled to approximately 70,000 in Q2 from 32,000 in Q1 2019. While StoneCo won’t appear cheap in 2020 due to its aggressive reinvestment strategy, its Wall Street-estimated top-line growth rate of 38% may have enough firepower to double this stock.

The facade of the Planet 13 SuperStore in Las Vegas, Nevada.

Image source: Planet 13.

8. Planet 13 Holdings

Although legalizing marijuana across the U.S. would make life easier for vertically integrated multistate operators (MSO), it’s not exactly a problem for Planet 13 Holdings (OTC:PLNHF), which approaches its seed-to-sale model a bit differently than other MSOs.

Planet 13 is all about creating the most unique experience imaginable for cannabis consumers. The company’s SuperStore in Las Vegas, Nevada, just west of the Strip, spans 112,000 square feet and will feature a pizzeria, coffee shop, events center, and consumer-facing processing site. At 112,000 square feet, it’s the largest dispensary in the U.S., and is actually 7,000 square feet bigger than the average Walmart. The company is also developing a second location that’ll open next year in Santa Ana, Calif., just minutes from Disneyland.

Aside from its sheer size and selection, Planet 13’s transparency and technology stand out. The company is utilizing self-pay kiosks in its stores to facilitate the payment process, and provides monthly updates on foot traffic and average paying ticket size for investors. Maybe most striking, Planet 13 has about 10% of Nevada’s entire cannabis market share. It could have its investors seeing green in 2020.

An up-close view of a shiny one ounce silver ingot.

Image source: Getty Images.

9. First Majestic Silver

Precious-metal mining isn’t exactly known as a high-growth industry. However, following years of conservative spending, and after witnessing gold and silver spot prices soar in 2019, miners like First Majestic Silver (NYSE:AG) are suddenly sitting pretty.

Even before gold and silver moved higher by a double-digit percentage in response to falling U.S. Treasury yields, First Majestic was making waves. In May 2018, it closed a deal to acquire Primero Mining and its flagship San Dimas mine. Between incorporating the low-cost San Dimas into its portfolio, and looking at ways to bolster its existing assets (e.g., modifying the roasting circuit at its La Encantada mine to add up to 1.5 million ounces of silver production per year), First Majestic has seen its silver equivalent ounce (SEO) production grow from 16.2 million ounces in 2017 to perhaps north of 26 million SEO in 2019.

First Majestic should also benefit from a return to historic norms in the gold-to-silver ratio (i.e., the amount of silver it takes to buy one ounce of gold). Historically, the gold-to-silver ratio has hovered around 65, but is currently at closer to 84. This would suggest silver has the potential to outperform gold in the intermediate-term; and no mining company has greater exposure to silver as a percentage of total revenue than First Majestic Silver.

A veterinarian with a stethoscope around her neck examining a small white dog.

Image source: Getty Images.

10. Trupanion

According to the American Pet Products Association, an estimated $75.4 billion will be spent on our pets in 2019, with $19 billion alone on veterinary care. Given that 63.4 million U.S. households have a dog, and 42.7 million have a cat, the opportunity for the pet insurance market is huge. That’s where Trupanion (NASDAQ:TRUP) comes in.

Trupanion is a provider of lifelong insurance policies for cats and dogs. Like any insurance company, Trupanion is built for long-term profitability. Most insurers offer predictable cash flow and have exceptional pricing power, which is a necessity if they’re to cover claims. But Trupanion is going where few insurers have gone before. U.S. and Canadian pet insurance market penetration is just 1% and 2%, respectively, which is providing some learning curve bumps along the way, but also giving Trupanion an incredibly long runway to growth.

Trupanion is currently unprofitable, but it appears close to turning the corner to profitability. Sales grew by 26% in the second quarter, and are expected to romp higher by 20% in 2020, according to Wall Street. If the company continues to find success with referrals, it’s very possible it could surprise in the earnings column next year.

A hacker wearing black gloves who's typing on a keyboard.

Image source: Getty Images.

11. Ping Identity

What do you get when you combine some of the hottest tech trends into one company? None other than identity solutions provider Ping Identity (NYSE:PING), which recently IPO’d in September.

While there are plenty of cybersecurity providers, Ping’s uniqueness derives from its use of artificial intelligence and machine learning to attempt to identify users and computers as trusted. Being able to operate within the confines of traditional enterprise networks, or being tasked with securing cloud networks, Ping offers an assortment of products that should be able to meet the needs of small, medium, and large-scale businesses. Not surprisingly, it should be capable of double-digit sales growth in the near-term, like its peers.

What also can’t be overlooked in the fast-growing security space is that Ping’s valuation is a modest $1.3 billion. After being acquired by private equity firm Vista Equity for $600 million in 2016, Ping delivered a doubling of that value in three years, following its IPO. This demonstrates the potential of focused individual security, and makes it all the more likely that Ping Identity could be quickly scooped up by a larger rival.

A woman checking her blood glucose readings on a connected device.

Image source: Livongo Health.

12. Livongo Health

As you’ve probably caught on by now, this list of stocks that could double in 2020 is full of disruptors, and Livongo Health (NASDAQ:LVGO) certainly fits the bill.

Livongo is a developer of solutions that helps people change their health habits. By supplying testing kits that connect to smartphones, and utilizing data science, Livongo works to change the behavior of diabetics, and can also be used to assist patients with hypertension. Given that over 30 million people have diabetes (most being type 2 diabetics), and a number of these folks could use some serious help managing their symptoms, Livongo Health’s products are exactly the disruptor needed in this space.

According to the company’s second-quarter results, the number of clients in Livongo’s ecosystem nearly doubled on a year-over-year basis to 720, while the number of enrolled diabetes members did more than double to 192,934. More importantly, Livongo’s triple-digit sales growth rate cannot be overlooked. While profits are highly unlikely in 2020, a year of market-topping revenue growth is very possible.

An assortment of couch sectionals pushed together in a living room.

Image source: Lovesac.

13. Lovesac

When the calendar changes to 2020, relax, put your feet up, and let small-cap Lovesac (NASDAQ:LOVE) do the heavy lifting for your portfolio.

Lovesac, the home furnishings company that sells beanbag chairs, sectional couches, and a host of other in-home decorations, has struggled in 2019 amid trade-war concerns. It’s been hit hard by higher tariff costs, and that’s clearly brought investor worry to the forefront.

However, a quick look at Lovesac’s second-quarter operating results should relieve most worries. By passing along modest price hikes to consumers, as well as reducing its reliance on China from 75% to 44% of its manufacturing, the company has, in a very short time frame, reduced the impact of the trade war going forward.

What’s more, these price hikes don’t appear to be adversely impacting the company’s fast-growing and niche furnishings business. Lovesac reiterated full-year sales growth of 40% to 45%, with comparable store sales growth coming in at 40.7% in the second quarter, and noted that new customers and repeat clients are driving growth. Although profitability is still probably two years away, sales growth of at least 40%, with a price-to-sales ratio of right around 1, could be more than enough to send this stock rocketing higher.

A lab researcher in a white coat holding a vial of blood in his left hand while reading from a blue clipboard in his right hand.

Image source: Getty Images.

14. Amarin

The biotech industry is always a good bet for a volatility, and Ireland-based Amarin (NASDAQ:AMRN) might have a real shot to grow from a midcap to a large-cap valuation in 2020 thanks to its lead drug, Vasecpa.

Vascepa, a purified fish oil derivative, was approved by the FDA all the way back in 2012 to treat patients with severe hypertriglyceridemia (SHTG). But it’s not Vascepa’s potential in treating SHTG patients that’s got Wall Street excited. Rather, it’s a supplemental new drug application stemming from a five-year Harvard study in 8,179 people with milder (but still high) triglyceride levels. The results showed that Vascepa lowered the aggregate risk of heart attack, stroke, and death in these patients by 25%. In other words, if Vascepa were to be approved for an expanded label indication to reduce the risk of major adverse cardiovascular events, its potential pool of patients could grow tenfold, as would its sales potential.

Later this month, on Nov. 14, an AdCom meeting will take place to discuss Amarin’s marketing application for Vascepa, as well as to vote on whether or not the members of the committee favor approval. By January 2020, at the latest, Amarin should have the FDA’s official decision on Vascepa (the FDA isn’t required to follow the AdCom’s vote, but it often does). If I were a betting man, I’d count on positive reviews all around.

A large city canvased by blue dots, representative of a wirelessly connected society.

Image source: Getty Images.

15. CalAmp

In Aug. 2018, Bain & Co. predicted that the Internet of Things global market would more than double from $235 billion in spending to $520 billion in just four years’ time (between 2017 and 2021). That global opportunity is too lucrative to overlook for small-cap CalAmp (NASDAQ:CAMP).

CalAmp, which provides software and subscription-based services, as well as cloud platforms that support a connected economy, has been hurt in recent quarters by the trade war with China, as well as sales weakness in its Telematics segment that’s been tied to a few core customers. However, CalAmp has reduced its Telematics product sourcing from China to around 50% from 70% to 80% earlier in the year, thereby minimizing the pain it feels from the trade war. Also, a number of customers blamed for its sales slowdown in Telematics (e.g., Caterpillar) are on the cusp of ramping up production as upgrades are made from 3G to 4G.

As Telematics growth picks back up, the company has seen record sales from its software subscription segment. Sales rose 65% year over year in the latest quarter, and now account for a third of total quarterly revenue. In short, the CalAmp growth story is just getting started, and 2020 could feature some very favorable year-on-year comparisons.

A female physician high-fiving a young child sitting on her mother's lap.

Image source: Getty Images.

16. Aimmune Therapeutics

Another biotech stock with a potential first-mover advantage in 2020 is Aimmune Therapeutics (NASDAQ:AIMT).

Aimmune’s lead drug is Palforzia, an oral drug that’s designed to lessen the symptoms associated with peanut allergy in children and teens. There is no FDA drug currently approved to treat peanut allergy in adolescents, and an estimated 4% to 6% of all children in the U.S. have some form of allergy to peanuts.

Now, here’s the great news: Palforzia looked like a star in late-stage clinical trials. Patients aged 4 to 17 were administered increasingly larger doses of peanut protein during the study, and 67.2% taking Palforzia completed the study without needing to discontinue the trial. This compared to a mere 4% on the placebo who completed the trial.

More good news: Palforzia has already been given the thumbs up by the FDA’s Allergenic Products Advisory Committee. Even though the FDA isn’t required to follow the vote of its panel of experts, it does so more often than not. It appears likely that Palforzia will get a green light in January, and it could be on track for more than $470 million in annual sales (by Wall Street’s consensus) by 2022. With other treatments in development for egg and walnut allergies, Aimmune looks well on its way to carving its own niche in the biotech space, and potentially doubling its stock in 2020.

Oil and gas pipeline leading to storage tanks.

Image source: Getty Images.

17. Antero Midstream

Midstream is the unsung hero of the energy infrastructure space. While drillers retrieve fossil fuels and refiners process them, it’s midstream providers that are the essential middlemen providing transmission, storage, and a host of other services that ensure these products make it to refineries for processing. Antero Midstream (NYSE:AM) may be just one of many midstream operators in the U.S., but it also might hold the distinction of being the cheapest and most likely to rebound in 2020.

Antero Midstream acts as the middleman for Antero Resources, a producer of natural gas and natural gas liquids (NGL) operating out of the Marcellus Shale and Utica Shale region in the Appalachia. This region is known for its natural gas and NGL production, which is worth noting given that LNG demand in North America could quadruple between 2018 and 2030, according to estimates from the McKinsey Energy/Insights Global Energy perspective model. This should provide a solid foundation of fee-based revenue for Antero Midstream.

Antero Midstream also recently announced a $300 million share repurchase program, suggesting that its board feels its stock is too cheap. If fully executed, this share buyback would remove about 8% of the company’s outstanding shares, and it shouldn’t impact the company’s jaw-dropping, yet seemingly sustainable, 17% dividend yield. Including this payout, Antero Midstream could very well double next year.

A gloved individual holding a full vial and dropper of cannabinoid-rich liquid in front of a hemp plant.

Image source: Getty Images.

18. MediPharm Labs

Marijuana stocks throughout Canada have suffered through supply issues since day one of adult-use legalization more than one year ago. But one ancillary niche that should be immune to these struggles is extraction services. The company you’ll want to know in this space is MediPharm Labs (OTC:MEDIF).

Extraction-service providers like MediPharm take cannabis and hemp biomass and produce resins, distillates, concentrates, and targeted cannabinoids for their clients. These are all used in the creation of high-margin derivatives, such as edibles and infused beverages, which were just legalized in Canada on Oct. 17, and will hit dispensary shelves in a little over a month. Since derivatives offer much juicier margins than dried cannabis flower, demand for cannabis and hemp extraction services should remain strong.

What’s more, extraction providers like MediPharm often secure contracts ranging from 18-to-36 months, leading to highly predictable cash flow. With MediPharm’s Barrie, Ontario, processing facility eventually on its way to 500,000 kilos of annual processing potential, and the company already profitable, it would not be the least bit surprising if MediPharm doubled in 2020.

A woman opening up a personalized box of clothing.

Image source: Stitch Fix.

19. Stitch Fix

Even high growth stocks can hit a rough patch; just ask the shareholders of online apparel company Stitch Fix (NASDAQ:SFIX). Following poorly received fourth-quarter results and weaker-than-expected sales guidance for the first quarter, Stitch Fix is a lot closer to its 52-week low than 52-week high at this point. However, things could change in a big way in 2020.

For starters, Stitch Fix is a potential retail disruptor that can capitalize on consumers in two ways. First, there’s the subscription side of the business that includes a stylist who picks outfits and accessories out for customers, who then to decide to keep (buy) or return these items. Secondly, but more recently, Stitch Fix has also been finding success with its direct buy program, which allows its members to skip the stylist and purchase highly curated and personalized product directly off its website. The company believes this dual-growth approach will play a key role in revenue growth reacceleration. It’s worth noting that despite its fourth-quarter report being poorly received by Wall Street, active clients grew 18% to 3.2 million from the prior-year period.

Stitch Fix is also planning to expand its offerings to men and children, and would be expected to bolster advertising as these new lines roll out. The company pointed out in its most recent quarter that fiscal first-quarter sales guidance is weaker because it lifted its foot off the gas pedal with regard to advertising. That’s an easy fix that should have Stitch Fix mending its weakness pretty quickly in 2020.

A white prescription generic drug tablet with a dollar sign stamped on it.

Image source: Getty Images.

20. Teva Pharmaceutical Industries

Not every stock that doubles has to be growing at 20%, 30%, or more, per year. Sometimes, it just requires Wall Street and investors to readjust their outlook.

Brand-name and generic drug giant Teva Pharmaceutical Industries (NYSE:TEVA) has had a miserable go of things for nearly four years. A combination of generic-drug pricing weakness, opioid lawsuits, bribery allegations, high debt levels, and the shelving of its once-hefty dividend, have sunk Teva’s stock by almost 90%. But a renaissance of sorts may be on the horizon.

You see, Teva lost more than half of its value in 2019 after 44 U.S. states sued the company, and many of its related peers, over the manufacture and sale of opioids. However, Teva appears to be making progress on these lawsuits by offering free medicine to select states, and, more importantly, not having to outlay much of its precious cash. If these opioid suits are resolved, it’s not crazy to think Teva regains pretty much all of the ground it lost when they were announced.

At the same time, Teva’s turnaround specialist, CEO Kare Schulze, has reduced annual operating expenses by $3 billion and lowered net debt by $8 billion in a couple of years. Teva has the potential to really change some opinions in 2020, and that could lead to a doubling in its share price.

A man in a tie who's holding a stopwatch behind an ascending stack of coins.

Image source: Getty Images.

Don’t forget the most important “secret” to wealth creation

While it’s possible that many, or only a small number, of these 20 companies doubles next year, the important thing for investors to remember is that great ideas often take time to develop. The grandiose secret to wealth creation isn’t going to be found by day-trading or trying to time the market. Rather, it’s discovered by investing in high-quality businesses that you believe in, and allowing your investments to grow for five, 10, or even 20 years, if not longer.

It can be fun to predict next year’s top performers and potentially find yourself a proverbial gold mine, but don’t take your eyes off the horizon, which is where the big money is being made.

10 stocks we like better than Stitch Fix

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Stitch Fix wasn’t one of them! That’s right — they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of June 1, 2019

Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool’s board of directors. Sean Williams owns shares of Exelixis, First Majestic Silver, Intercept Pharmaceuticals, and Teva Pharmaceutical Industries. The Motley Fool owns shares of and recommends Facebook, Livongo Health Inc, Pinterest, Stitch Fix, and Trupanion. The Motley Fool owns shares of Stoneco LTD. The Motley Fool recommends CalAmp, Exelixis, Innovative Industrial Properties, Intercept Pharmaceuticals, and Redfin. The Motley Fool has a disclosure policy.

This Marijuana Stock Could be Like Buying Amazon for $3.19
A little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming.

Cannabis legalization is sweeping over North America – 10 states plus Washington, D.C., have all legalized recreational marijuana over the last few years, and full legalization came to Canada in October 2018.

And one under-the-radar Canadian company is poised to explode from this coming marijuana revolution.

Because a game-changing deal just went down between the Ontario government and this powerhouse company…and you need to hear this story today if you have even considered investing in pot stocks.

Simply click here to get the full story now.

Sean Williams

Sean Williams

(TMFUltraLong)

Learn more

Source: https://www.fool.com/investing/2019/11/11/20-stocks-that-could-double-your-money-in-2020.aspx

11.7K subscribers
GROWTH STOCKS THAT WILL DOUBLE YOUR MONEY! Stocks that will double your money. Top Stocks To Buy for 2020. Analysts forecast that over the long term Disney could potentially reach 160 Million Subscribers. Even with all those potential customers $7 per subscriber will translate into huge income for Disney. If Disney hit 50 million subscribers, that would generate revenue of between $3 billion and $5 billion in the first full year alone. At 160 million subscribers, we’re talking between $9 billion and $13 billion annually. To put that into perspective, Disney produced $59 billion in fiscal 2018. If Disney were to achieve these estimates, it could increase its revenue by between 5% and 7% in the first year and could eventually boost its top line by between 16% and 22%. Hulu Is Growing Faster Than Netflix The streaming service released some end-of-year numbers. Hulu ended 2018 with over 25 million subscribers. That’s more than 8 million more than last year and a 48% year-over-year increase. That’s better growth than Netflix (NASDAQ:NFLX) on both a relative and absolute basis in the United States. For reference, Netflix added 5.7 million U.S. subscribers in the 12 months ended in September.Is Disney Stock A Buy? DISNEY STOCK 2019| DISNEY STOCK ANALYSIS (Top Growth Stocks 2019). Costco Stock|Disney Stock| Growth Stock Investing 2019. Costco Net sales totaled $138 billion, an increase of 9.7 percent, with a comparable sales increase of 9 percent. Net income for the 52-week fiscal year was $3.134 billion, or $7.09 per share, an increase of 17 percent. Revenue from membership fees increased 10.1 percent to $3.142 billion.In 2018, Costco reached a milestone with 750􏰀􏰁 warehouse locations. Fiscal 2018 expansion included the opening of 21 new warehouses around the globe, the 100th location in Canada. Costco continues adding gas stations and other ancillary services to locations in different countries. In 2019, Costco expects to open 23 new warehouses and relocate up to 4 warehouses to more ideal locations. Growth Stock Investing. Dividend Stock Investing. Undervalued Stocks 2019. Best Stocks 2019. Top Stocks 2019. Stock Market. Stocks. Best Growth Stocks 2019. Best Growth Stocks 2019. Best Growth Stocks to buy 2019. Top Growth stock picks 2019. Best technology stocks to buy 2019. Top investments 2019. Best investments 2019. Best stocks to buy and hold forever. Top stocks to buy 2019. #stocks #stockmarket #investing

%d bloggers like this:
Skip to toolbar